Compumedics (ASX:CMP) Momentum Rank: 7 (As of Jul. 12, 2026) — 75% Above Median


ASX:CMP Compumedics Ltd ASX:CMP
62 GF Score
Price A$0.23
GF Value A$0.32
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Compumedics Momentum Rank?

Compumedics ASX:CMP +4.55% 62 Momentum Rank is 7 as of Jul. 12, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates ASX:CMP with a GF Score™ of 62/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Compumedics has the Momentum Rank of 7.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Compumedics Momentum Rank Related Terms

ASX:CMP vs ABT, SYK, MDT: Momentum Rank Comparison

For the Medical Devices subindustry, Compumedics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compumedics Momentum Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Compumedics's Momentum Rank falls into.


ASX:CMP
62GF Score
Compumedics Ltd ASX:CMP
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 7 mean?
Compumedics (ASX:CMP) has a Momentum Rank of 7 as of Jul. 12, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Compumedics and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Compumedics' Momentum Rank has ranged from 1.00 to 10.00.
Is Compumedics' Momentum Rank too high?
Compumedics' current Momentum Rank of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Compumedics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Momentum Rank compare to ABT and SYK?
Compumedics' Momentum Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Compumedics' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Devices & Instruments company?
A good Momentum Rank depends on the Medical Devices & Instruments industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Compumedics and its competitors. Compumedics's current Momentum Rank is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.23 — trading 28.1% below its estimated fair value. The current Momentum Rank is 7, which is 75% above median its 10-year median of 4.00. Compumedics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Momentum Rank is 7 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compumedics (ASX:CMP) Overvalued in 2026?

Based on GuruFocus' analysis, Compumedics stock appears to be undervalued. The current stock price of A$0.23 is trading 28.1% below its estimated GF Value™ of A$0.32. GuruFocus considers Compumedics to be Modestly Undervalued.

Key valuation signals for ASX:CMP:

  • Momentum Rank: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: A$0.32 vs. price of A$0.23 (28.1% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compumedics Business Description

Address 30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
62GF Score

Get the complete analysis for ASX:CMP

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.23
Price
A$0.32
GF Value